Pharmacologically active drug metabolites: Impact on drug discovery and pharmacotherapy

Pharmacological Reviews

Volumn 65, Issue 2, 2013, Pages 578-640

  Scott Obach, R ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ALLOPURINOL; ARTESUNATE; ASTEMIZOLE; BUSPIRONE; CHLORDIAZEPOXIDE; CLOMIFENE; CODEINE; DEXTROPROPOXYPHENE; DIHYDROERGOTAMINE; DIPHENOXYLATE; DOLASETRON MESILATE; DRUG METABOLITE; EBASTINE; FLUTAMIDE; HYDROXYZINE; IRINOTECAN; LORATADINE; LOSARTAN; OXCARBAZEPINE; OXYBUTYNIN; PROCAINAMIDE; REMACEMIDE; RISPERIDONE; ROFLUMILAST; SIBUTRAMINE; TAMOXIFEN; TERFENADINE; THIOCOLCHICOSIDE; UNINDEXED DRUG;

ARTICLE; BINDING AFFINITY; CLINICAL RESEARCH; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; MEMBRANE PERMEABILITY; PRIORITY JOURNAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG THERAPY; OXIDATION REDUCTION REACTION; PLASMA PROTEIN BINDING;

ABSORPTION; ANIMALS; BIOTRANSFORMATION; DRUG DISCOVERY; HUMANS; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 84873908108     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.111.005439     Document Type: Article

References (373)

1. Abilify (2012) Product label. Otsuka America Pharmaceutical, Rockville, MD.
2. Actos (2011) Product label. Takeda Pharmaceuticals U.S.A., Deerfield, IL.
3. Abshagen U, Rennekamp H, and Luszpinski G (1976) Pharmacokinetics of spironolactone in man. Naunyn-Schmiedeberg Arch Pharmacol 296:37-45.
4. Addison RS, Parker-Scott SL, Eadie MJ, Hooper WD, and Dickinson RG (2000) Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers. Eur J Clin Pharmacol 56:715-721.
5. Adkison KDK, Ojemann GA, Rapport RL, Dills RL, and Shen DD (1995) Distribution of unsaturated metabolites of valproate in human and rat brain-pharmacologic relevance? Epilepsia 36:772-782.
6. Agnel M, Esnaud H, Langer SZ, and Graham D (1996) Pharmacological characterization of the cloned human 5-hydroxytryptamine transporter. Biochem Pharmacol 51:1145-1151.
7. Alderdice MT and McMillan JE (1982) Comparison of the effects of trimethadione and its primary metabolite dimethadione on neuromuscular function and the effects of altered pH on the actions of dimethadione. J Pharmacol Exp Ther 221:547-551.
8. Anthes JC, Gilchrest H, Richard C, Eckel S, Hesk D, West RE Jr, Williams SM, Greenfeder S, Billah M, and Kreutner W, et al. (2002) Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol 449:229-237.
9. Antila S, Pesonen U, Lehtonen L, Tapanainen P, Nikkanen H, Vaahtera K, and Scheinin H (2004) Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci 23:213-222.
10. Antoniades C, Tousoulis D, Koumallos N, Marinou K, and Stefanadis C (2007) Levosimendan: beyond its simple inotropic effect in heart failure. Pharmacol Ther 114: 184-197.
11. Anzemet (2011) Product label. Aaofi-Aventis U.S., Bridgewater, NJ.
12. Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL, and Lemberger L (1984) Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 36:138-144.
13. Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, and Huang Q, et al. (2005) Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:5025-5037.
14. Augustijns P and Verbeke N (1993) Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. Clin Pharmacokinet 24: 259-269.
15. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, and Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
16. Barbhaiya RH, Buch AB, and Greene DS (1996) A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 16:19-25.
17. Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, and Jessen L (1998) Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 18:295-301.
18. Basil B and Jordan R (1982) Pharmacological properties of diacetolol (M & B 16,942), a major metabolite of acebutolol. Eur J Pharmacol 80:47-56.
19. Bauer TM, Ritz R, Haberthür C, Ha HR, Hunkeler W, Sleight AJ, Scollo-Lavizzari G, and Haefeli WE (1995) Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 346:145-147.
20. Bélanger A, Giasson M, Couture J, Dupont A, Cusan L, and Labrie F (1988) Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. Prostate 12:79-84.
21. Bertilsson L, Otani K, Dahl ML, Nordin C, and Aberg-Wistedt A (1991) Stereoselective efflux of (E)-10-hydroxynortriptyline enantiomers from the cerebrospinal fluid of depressed patients. Pharmacol Toxicol 68:100-103.
22. Bertilsson L and Tomson T (1986) Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet 11:177-198.
23. Bertilsson L, Braithwaite R, Tybring G, Garle M, and Borgå O (1979) Techniques for plasma protein binding of demethylchlorimipramine. Clin Pharmacol Ther 26: 265-271.
24. Bhattacharjee AK and Karle JM (1998) Functional correlation of molecular electronic properties with potency of synthetic carbinolamine antimalarial agents. Bioorg Med Chem 6:1927-1933.
25. Bilezikian JP, Dornfeld AM, and Gammon DE (1978) Structure-binding-activity analysis of beta-adrenergic amines-II. Binding to the beta receptor and inhibition of adenylate cyclase. Biochem Pharmacol 27:1455-1461.
26. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, and Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386-399.
27. Böhmer GM, Nassr N, Wenger M, Hünnemeyer A, Lahu G, Templin S, Gleiter CH, and Hermann R (2009) The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions. J Clin Pharmacol 49: 389-397.
28. Bolo NR, Hodé Y, Nédélec JF, Lainé E, Wagner G, and Macher JP (2000) Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23: 428-438.
29. Boppana VK (1995) Simultaneous determination of granisetron and its 7-hydroxy metabolite in human plasma by reversed-phase high-performance liquid chromatography utilizing fluorescence and electrochemical detection. J Chromatogr A 692: 195-202.
30. Borgå O, Azarnoff DL, Forshell GP, and Sjöqvist F (1969) Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol 18:2135-2143.
31. Bourassa P, Dubeau S, Maharvi GM, Fauq AH, Thomas TJ, and Tajmir-Riahi HA (2011) Binding of antitumor tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen to human serum albumin. Biochimie 93:1089-1101.
32. Boxenbaum HG, Geitner KA, Jack ML, Dixon WR, and Kaplan SA (1977) Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HC1 in healthy subjects: multiple-dose oral administration. J Pharmacokinet Biopharm 5:25-39.
33. Boyd RA, Chin SK, Don-Pedro O, Verotta D, Sheiner LB, Williams RL, and Giacomini KM (1989) The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. Clin Pharmacol Ther 46:408-419.
34. Breyer-Pfaff U, Gaertner HJ, Kreuter F, Scharek G, Brinkschulte M, and Wiatr R (1982) Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels. Psychopharmacology (Berl) 76:240-244.
35. Brown SM, Holtzman M, Kim T, and Kharasch ED (2011) Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 115:1251-1260.
36. Brynne N, Dalén P, Alván G, Bertilsson L, and Gabrielsson J (1998) Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther 63:529-539.
37. Buhl AE, Waldon DJ, Baker CA, and Johnson GA (1990) Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol 95:553-557.
38. Bun H, Coassolo P, Gouezo F, Serradimigni A, and Cano JP (1986) Time-dependence of clobazam and N-demethylclobazam kinetics in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 24:287-293.
39. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, and Hacksell U, et al. (2005) Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite Ndesmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 315: 1278-1287.
40. Busch AE, Suessbrich H, Kunzelmann K, Hipper A, Greger R, Waldegger S, Mutschler E, Lindemann B, and Lang F (1996) Blockade of epithelial Na+ channels by triamterenes-underlying mechanisms and molecular basis. Pflugers Arch 432: 760-766.
41. Butz RF, Welch RM, and Findlay JWA (1982) Relationship between bupropion disposition and dopamine uptake inhibition in rats and mice. J Pharmacol Exp Ther 221:676-685.
42. Caccia S, Conti I, Viganò G, and Garattini S (1986) 1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. Pharmacology 33:46-51.
43. Caccia S and Garattini S (1990) Formation of active metabolites of psychotropic drugs. An updated review of their significance. Clin Pharmacokinet 18:434-459.
44. Callegari E, Malhotra B, Bungay PJ, Webster R, Fenner KS, Kempshall S, LaPerle JL, Michel MC, and Kay GG (2011) A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 72:235-246.
45. Calvo B, García MJ, Pedraz JL, Mariño EL, and Domínguez-Gil A (1985) Pharmacokinetics of amoxapine and its active metabolites. Int J Clin Pharmacol Ther Toxicol 23:180-185.
46. Camptosar (2012) Product label. Pfizer, New York, NY.
47. Catalano A, Carocci A, Fracchiolla G, Franchini C, Lentini G, Tortorella V, De Luca A, De Bellis M, Desaphy JF, and Conte Camerino D (2004) Stereospecific synthesis of "para-hydroxymexiletine" and sodium channel blocking activity evaluation. Chirality 16:72-78.
48. Chen X, Zhong D, Xu H, Schug B, and Blume H (2002) Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 768:267-275.
49. Chen C (2008) Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem 15: 2173-2191.
50. Cheetham SC, Viggers JA, Butler SA, Prow MR, and Heal DJ (1996) [3H]nisoxetine-a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H] noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology 35:63-70.
51. Cheung SW, Tang SW, and Remington G (1991) Simultaneous quantitation of loxapine, amoxapine and their 7-and 8-hydroxy metabolites in plasma by highperformance liquid chromatography. J Chromatogr A 564:213-221.
52. Chien YW, Hofmann LM, Lambert HJ, and Tao LC (1976) Binding of spirolactones to human plasma proteins. J Pharm Sci 65:1337-1340.
53. Christians U, Kohlhaw K, Budniak J, Bleck JS, Schottmann R, Schlitt HJ, Almeida VM, Deters M, Wonigeit K, and Pichlmayr R, et al. (1991) Ciclosporin metabolite pattern in blood and urine of liver graft recipients. I. Association of ciclosporin metabolites with nephrotoxicity. Eur J Clin Pharmacol 41:285-290.
54. Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FYF, and McCann B, et al. (2008) Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 36:1357-1364.
55. Chung M, Hilbert JM, Gural RP, Radwanski E, Symchowicz S, and Zampaglione N (1984) Multiple-dose quazepam kinetics. Clin Pharmacol Ther 35:520-524.
56. Cioli D, Pica-Mattoccia L, and Archer S (1995) Antischistosomal drugs: past, present. and future? Pharmacol Ther 68:35-85.
57. Clarke SE, Austin NE, Bloomer JC, Haddock RE, Higham FC, Hollis FJ, Nash M, Shardlow PC, Tasker TC, and Woods FR, et al. (1994) Metabolism and disposition of 14C-granisetron in rat, dog and man after intravenous and oral dosing. Xenobiotica 24:1119-1131.
58. Clements JA, Nimmo WS, and Grant IS (1982) Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 71:539-542.
59. Cooke RG, Warsh JJ, Stancer HC, Reed KL, and Persad E (1984) The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma. Clin Pharmacol Ther 36:343-349.
60. Coombs TJ, Coulson CJ, and Smith VJ (1980) Blood plasma binding of acebutolol and diacetolol in man. Br J Clin Pharmacol 9:395-397.
61. Copeland KR, Yatscoff RW, and McKenna RM (1990) Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance. Clin Chem 36:225-229.
62. Cozaar (2011) Product label. Merck Sharp & Dohme Corp., Whitehouse Station, NJ.
63. Creek DJ, Charman WN, Chiu FCK, Prankerd RJ, Dong Y, Vennerstrom JL, and Charman SA (2008) Relationship between antimalarial activity and heme alkylation for spiro-and dispiro-1,2,4-trioxolane antimalarials. Antimicrob Agents Chemother 52:1291-1296.
64. Crestor (2012) Product label. AstraZeneca, London, UK.
65. Dahl ML, Bertilsson L, and Nordin C (1996) Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology (Berl) 123:315-319.
66. Dalén P, Alvan G, Wakelkamp M, and Olsen H (1996) Formation of meprobamate from carisoprodol is catalysed by CYP2C19. Pharmacogenetics 6:387-394.
67. Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, Lukas RJ, and Martin BR (2004) Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66:675-682.
68. Dangman KH and Hoffman BF (1981) In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide. J Pharmacol Exp Ther 217: 851-862.
69. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, and Williams KM (2007) Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 46:623-644.
70. De Bellis M, De Luca A, Rana F, Cavalluzzi MM, Catalano A, Lentini G, Franchini C, Tortorella V, and Conte Camerino D (2006) Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents. Br J Pharmacol 149:300-310.
71. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, and Pinder RM (1988) Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 27:399-408.
72. De Bono G, Kaye CM, Roland E, and Summers AJ (1985) Acebutolol: ten years of experience. Am Heart J 109:1211-1213.
73. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, and Andree TH (2006) Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 318:657-665.
74. Deupree JD, Montgomery MD, and Bylund DB (2007) Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram. Eur J Pharmacol 576:55-60.
75. Dickinson RG, Hooper WD, Dunstan PR, and Eadie MJ (1989) First dose and steadystate pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. Eur J Clin Pharmacol 37:69-74.
76. Dixon R, Brooks MA, Postma E, Hackman MR, Spector S, Moore JD, and Schwartz MA (1976) N-desmethyldiazepam: a new metabolite of chlordiazepoxide in man. Clin Pharmacol Ther 20:450-457.
77. Dixon R, Gillotin C, Gibbens M, Posner J, and Peck RW (1997) The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. Br J Clin Pharmacol 43:273-281.
78. Dockens RC, Salazar DE, Fulmor IE, Wehling M, Arnold ME, and Croop R (2006) Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range. J Clin Pharmacol 46: 1308-1312.
79. Dong H, Xu F, Zhang Z, Tian Y, and Chen Y (2006) Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLCAPCI-MS. J Mass Spectrom 41(4, Spec.)477-486.
80. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, and Cianfrogna J, et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33: 165-174.
81. Drayer DE (1976) Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure. Clin Pharmacokinet 1:426-443.
82. Drayer DE, Lorenzo B, Werns S, and Reidenberg MM (1983) Plasma levels, protein binding, and elimination data of lidocaine and active metabolites in cardiac patients of various ages. Clin Pharmacol Ther 34:14-22.
83. Easmon CS, Ison CA, Kaye CM, Timewell RM, and Dawson SG (1982) Pharmacokinetics of metronidazole and its principal metabolites and their activity against Gardnerella vaginalis. Br J Vener Dis 58:246-249.
84. Ebert B, Mikkelsen S, Thorkildsen C, and Borgbjerg FM (1997) Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 333:99-104.
85. Eberts FS Jr, Philopoulos Y, Reineke LM, and Vliek RW (1981) Triazolam disposition. Clin Pharmacol Ther 29:81-93.
86. Ebner T, Wagner K, and Wienen W (2010) Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos 38:1567-1575.
87. Ejsing TB, Pedersen AD, and Linnet K (2005) P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drugdrug interaction experiments. Hum Psychopharmacol 20:493-500.
88. Elkader A and Sproule B (2005) Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 44:661-680.
89. Ereshefsky L (1999) Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 60 (Suppl 10):20-30.
90. Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, and Maudelonde T (2009) Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites. J Steroid Biochem Mol Biol 116: 8-14.
91. Fang J, Bourin M, and Baker GB (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn-Schmiedeberg Arch Pharmacol. 359:147-151.
92. Féau C, Arnold LA, Kosinski A, and Guy RK (2009) A high-throughput ligand competition binding assay for the androgen receptor and other nuclear receptors. J Biomol Screen 14:43-48.
93. Fernandez C, Maradeix V, Gimenez F, Thuillier A, and Farinotti R (1993) Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab Dispos 21:1125-1128.
94. Fernandez C, Martin C, Gimenez F, and Farinotti R (1995) Clinical pharmacokinetics of zopiclone. Clin Pharmacokinet 29:431-441.
95. Ferry DR, Glossmann H, and Kaumann AJ (1985) Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart. Br J Pharmacol 84:811-824.
96. Field JB, Ohta M, Boyle C, and Remer A (1967) Potentiation of acetohexamide hypoglycemia by phenylbutazone. N Engl J Med 277:889-894.
97. Fleck MW (2002) Molecular actions of (S)-desmethylzopiclone (SEP-174559) an anxiolytic metabolite of zopiclone. J Pharmacol. Exp Ther 302:612-618.
98. Freedberg KA, Innis RB, Creese I, and Snyder SH (1979) Antischizophrenic drugs: differential plasma protein binding and therapeutic activity. Life Sci 24: 2467-2473.
99. Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, and Antonsson M (2009) Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 52:6233-6243.
100. Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K, and Azuma J (1999) Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 47:450-453.
101. Funder JW, Mercer J, and Hood J (1976) SC 23992: radioreceptor assays for therapeutic and side effects. Clin Sci Mol Med 51(Suppl 3: Proceedings, Fourth Meeting, International Society of Hypertension): 333S-334S.
102. Fura A, Shu YZ, Zhu M, Hanson RL, Roongta V, and Humphreys WG (2004) Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. J Med Chem 47:4339-4351.
103. Fura A (2006) Role of pharmacologically active metabolites in drug discovery and development. Drug Discov Today 11:133-142.
104. Fura A, Khanna A, Vyas V, Koplowitz B, Chang SY, Caporuscio C, Boulton DW, Christopher LJ, Chadwick KD, and Hamann LG, et al. (2009) Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 37:1164-1171.
105. Furlong MT, Agrawal S, Hawthorne D, Lago M, Unger S, Krueger L, and Stouffer B (2012) A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study. J Pharm Biomed Anal 58:130-135.
106. Furr BJ and Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205.
107. Gaillard P, Carrupt PA, and Testa B (1994) The conformation-dependent lipophilicity of morphine glucuronides as calculated from their molecular lipophilicity potential. Bioorg Med Chem Lett 4:737-742.
108. Gao Y, Zhang LR, and Fu Q (2008) CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol 64:877-882.
109. Garzone PD and Kroboth PD (1989) Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 16:337-364.
110. Gengo FM, Ulatowski JA, and McHugh WB (1984) Metoprolol and alphahydroxymetoprolol concentrations and reduction in essential tremor. Clin Pharmacol Ther 36:320-325.
111. Ghabrial H, Desmond PV, Watson KJ, Gijsbers AJ, Harman PJ, Breen KJ, and Mashford ML (1986) The effects of age and chronic liver disease on the elimination of temazepam. Eur J Clin Pharmacol 30:93-97.
112. Giacomini KM, Gibson TP, and Levy G (1978) Plasma protein binding of dpropoxyphene in normal subjects and anephric patients. J Clin Pharmacol 18: 106-109.
113. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, and Flockhart DA, et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318.
114. Goldberg MR, Lee Y, Vyas KP, Slaughter DE, Panebianco D, Ermlich SJ, Shadle CR, Brucker MJ, McLoughlin DA, and Olah TV (2000) Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single-and multiple-dose tolerability and pharmacokinetics in healthy subjects. J Clin Pharmacol 40:74-83.
115. Golden RN, De Vane CL, Laizure SC, Rudorfer MV, Sherer MA, and Potter WZ (1988) Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry 45:145-149.
116. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, and Dillon GH (2009) Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther 329:827-837.
117. Gopalakrishnan M, Molinari EJ, Shieh CC, Monteggia LM, Roch JM, Whiteaker KL, Scott VES, Sullivan JP, and Brioni JD (2000) Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells. Br J Pharmacol 129:1323-1332.
118. Greenblatt DJ, Shader RI, Franke K, and Harmatz JS (1978) Pharmacokinetics of chlordiazepoxide and metabolites following single and multiple oral doses. Int J Clin Pharmacol Biopharm 16:486-493.
119. Gregory RE and Ettinger DS (1998) 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. Acomparison of their pharmacology and clinical efficacy. Drugs 55:173-189.
120. Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, Hayes M, Pokorny R, Seiberling M, and Ben-Am M, et al. (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33:1503-1512.
121. Guengerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611-650.
122. Hagen AE, Obach RS, O'Connell TN, Schmidt AW, and Pollard EB (2008) Impact of the identification of an active metabolite on the development of CE-210666, a 5HT1B antagonist. Drug Metab Rev 40:208.
123. Hanoun N, Saurini F, Lanfumey L, Hamon M, and Bourgoin S (2003) Dihydroergotamine and its metabolite, 89-hydroxy-dihydroergotamine, as 5-HT1A receptor agonists in the rat brain. Br J Pharmacol 139:424-434.
124. Hardy DJ, Swanson RN, Rode RA, Marsh K, Shipkowitz NL, and Clement JJ (1990) Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 34:1407-1413.
125. Hargreaves RJ (2000) Pharmacology and potential mechanisms of action of rizatriptan. Cephalalgia 20 (Suppl 1):2-9.
126. Harron DWG and Brogden RN (1990) Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. Drugs 39:720-740.
127. Heykants J (1984) The pharmacokinetics and metabolism of astemizole in man, in Astemizole: New Non-Sedating Long-Acting H1-Antagonist, pp 25-34, Medicine Publishing Foundation Symposium Series 11.
128. Hijazi Y and Boulieu R (2002) Protein binding of ketamine and its active metabolites to human serum. Eur J Clin Pharmacol 58:37-40.
129. Hill RJ, Duff HJ, and Sheldon RS (1988) Determinants of stereospecific binding of type I antiarrhythmic drugs to cardiac sodium channels. Mol Pharmacol 34: 659-663.
130. Hinderling PH, Bres J, and Garrett ER (1974) Protein binding and erythrocyte partitioning of disopyramide and its monodealkylated metabolite. J Pharm Sci 63: 1684-1690.
131. Hinderling PH and Garrett ER (1976) Pharmacodynamics of the antiarrhythmic disopyramide in healthy humans: correlation of the kinetics of the drug and its effects. J Pharmacokinet Biopharm 4:231-242.
132. Houston JB (1981) Drug metabolite kinetics. Pharmacol Ther 15:521-552.
133. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, and Jonkman JH (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54:257-268.
134. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, and Buchmann S, et al. (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327:736-745.
135. Inturrisi CE, Colburn WA, Verebey K, Dayton HE, Woody GE, and O'Brien CP (1982) Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. Clin Pharmacol Ther 31:157-167.
136. Ito K, Asakura A, Yamada Y, Nakamura K, Sawada Y, and Iga T (1997) Prediction of the therapeutic dose for benzodiazepine anxiolytics based on receptor occupancy theory. Biopharm Drug Dispos 18:293-303.
137. Iyer L and Ratain MJ (1998) Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol 42 (Suppl):S31-S43.
138. Jandu KS, Barrett V, Brockwell M, Cambridge D, Farrant DR, Foster C, Giles H, Glen RC, Hill AP, and Hobbs H, et al. (2001) Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation. J Med Chem 44:681-693.
139. Jaillon P, Rubenson D, Peters F, Mason JW, and Winkle RA (1981) Electrophysiologic effects of N-acetylprocainamide in human beings. Am J Cardiol 47: 1134-1140.
140. Javaid JI, Perel JM, and Davis JM (1979) Inhibition of biogenic amines uptake by imipramine, desipramine, 2 OH-imipramine and 2 OH-desipramine in rat brain. Life Sci 24:21-28.
141. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, and Araba A, et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Nat Cancer Inst 97:30-39.
142. Johannessen SI, Gerna M, Bakke J, Strandjord RE, and Morselli PL (1976) CSF concentrations and serum protein binding of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients. Br J Clin Pharmacol 3:575-582.
143. Johnson MD, Westley BR, and May FEB (1989) Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells. Br J Cancer 59:727-738.
144. Johnson KE, Balderston SM, Pieper JA, Mann DE, and Reiter MJ (1991) Electrophysiologic effects of verapamil metabolites in the isolated heart. J Cardiovasc Pharmacol 17:830-837.
145. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, and Skaar TC (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159.
146. Jonkers RE, Koopmans RP, Portier EJG, and van Boxtel CJ (1991) Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. J Pharmacol Exp Ther 256:959-966.
147. Joy MS, Dornbrook-Lavender K, Blaisdell J, Hilliard T, Boyette T, Hu Y, Hogan SL, Candiani C, Falk RJ, and Goldstein JA (2009) CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Eur J Clin Pharmacol 65:947-953.
148. Jung H, Hurtado M, Sanchez M, Medina MT, and Sotelo J (1992) Clinical pharmacokinetics of albendazole in patients with brain cysticercosis. J Clin Pharmacol 32: 28-31.
149. Kodobayashi M, Yamamoto K, Takahara S, Okuyama A, Takashima N, Sawada M, Yanaihara C, and Kurokawa N (1995) Gel chromatographic analysis of cyclosporin and its metabolites in human blood compartments. J Pharm Pharmacol 47: 693-697.
150. Kaila T and Iisalo E (1993) Selectivity of acebutolol, atenolol, and metoprolol in healthy volunteers estimated by the extent the drugs occupy beta 2-receptors in the circulating plasma. J Clin Pharmacol 33:959-966.
151. Kalliokoski A, Neuvonen M, Neuvonen PJ, and Niemi M (2008) No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br J Clin Pharmacol 65:78-86.
152. Kamei C, Mio M, Izushi K, Kitazumi K, Tsujimoto S, Fujisawa K, Adachi Y, and Tasaka K (1991) Antiallergic effects of major metabolites of astemizole in rats and guinea pigs. Arzneimittelforschung 41:932-936.
153. Kang MJ, Song WH, Shim BH, Oh SY, Lee HY, Chung EY, Sohn Y, and Lee J (2010) Pharmacologically active metabolites of currently marketed drugs: potential resources for new drug discovery and development. Yakugaku Zasshi 130: 1325-1337.
154. Karim A, Ranney RE, Evensen KL, and Clark ML (1972) Pharmacokinetics and metabolism of diphenoxylate in man. Clin Pharmacol Ther 13:407-419.
155. Karlsson L, Schmitt U, Josefsson M, Carlsson B, Ahlner J, Bengtsson F, Kugelberg FC, and Hiemke C (2010) Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur Neuropsychopharmacol 20:632-640.
156. Kawato Y, Aonuma M, Hirota Y, Kuga H, and Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191.
157. Keung ACF, Landriault H, Lefebvre M, Gossard D, Dempsey EE, Juneau M, Dimmitt D, Castles M, Roberts L, and Spenard J (1997) Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women. Biopharm Drug Dispos 18:361-369.
158. Kilpatrick GJ and Smith TW (2005) Morphine-6-glucuronide: actions and mechanisms. Med Res Rev 25:521-544.
159. Kim KA, Song WK, and Park JY (2009) Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin Pharmacol Ther 86:511-518.
160. Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lötsch J, Roots I, and Brockmöller J (2007) Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 7: 257-265.
161. Kirschbaum KM, Uhr M, Holthoewer D, Namendorf C, Pietrzik C, Hiemke C, and Schmitt U (2010) Pharmacokinetics of acute and sub-chronic aripiprazole in Pglycoprotein deficient mice. Neuropharmacology 59:474-479.
162. Kivikko M, Sundberg S, Karlsson MO, Pohjanjousi P, and Colucci WS (2011) Acetylation status does not affect levosimendan's hemodynamic effects in heart failure patients. Scand Cardiovasc J 45:86-90.
163. Kivikko M, Antila S, Eha J, Lehtonen L, and Pentikäinen PJ (2002) Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 40: 465-471.
164. Kivistö KT, Niemi M, Schaeffeler E, Pitkälä K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, and Strandberg T (2004) Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14:523-525.
165. Kochansky CJ, McMasters DR, Lu P, Koeplinger KA, Kerr HH, Shou M, and Korzekwa KR (2008) Impact of pH on plasma protein binding in equilibrium dialysis. Mol Pharm 5:438-448.
166. Kodama I, Kamiya K, and Toyama J (1997) Cellular electropharmacology of amiodarone. Cardiovasc Res 35:13-29.
167. Kojima K, Yamamoto K, Fujioka H, and Kaneko H (1985) Pharmacokinetics of spironolactone and potassium canrenoate in humans. J Pharmacobiodyn 8:161-166.
168. Kool J, Ramautar R, van Liempd SM, Beckman J, de Kanter FJJ, Meerman JHN, Schenk T, Irth H, Commandeur JNM, and Vermeulen NPE (2006) Rapid on-line profiling of estrogen receptor binding metabolites of tamoxifen. J Med Chem 49: 3287-3292.
169. Krieter PA, Colletti AE, Doss GA, and Miller RR (1994) Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. Drug Metab Dispos 22: 625-630.
170. Kretz O, Weiss HM, Schumacher MM, and Gross G (2004) In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br J Clin Pharmacol 58:212-216.
171. Kristensen CB, Gram LF, and Kragh-Sørensen P (1985) Mianserin protein binding in serum and plasma from healthy subjects and patients with depression and rheumatoid arthritis. Psychopharmacology (Berl) 87:204-206.
172. Kuoppamäki M, Syvälahti E, and Hietala J (1993) Clozapine and Ndesmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol 245:179-182.
173. Lahu G, Hünnemeyer A, Diletti E, Elmlinger M, Ruth P, Zech K, McCracken N, and Facius A (2010) Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model. Clin Pharmacokinet 49:589-606.
174. Lai J, Ma SW, Porreca F, and Raffa RB (1996) Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur J Pharmacol 316:369-372.
175. Lajer M, Tarnow L, Andersen S, and Parving HH (2007) CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathy. Diabet Med 24:323-325.
176. Lalonde RL, Lessard D, and Gaudreault J (1996) Population pharmacokinetics of terfenadine. Pharm Res 13:832-838.
177. Lambert WE, Meyer E, De Leenheer AP, De Bersaques J, and Kint AH (1992) Pharmacokinetics and drug interactions of etretinate and acitretin. J Am Acad Dermatol 27:S19-S22.
178. Larsen FG, Jakobsen P, Larsen CG, Kragballe K, and Nielsen-Kudsk F (1988) Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. Pharmacol Toxicol 62:159-165.
179. Le MT, Vanderheyden PML, Szaszák M, Hunyady L, Kersemans V, and Vauquelin G (2003) Peptide and nonpeptide antagonist interaction with constitutively active human AT1 receptors. Biochem Pharmacol 65:1329-1338.
180. le Coutre P, Kreuzer KA, Pursche S, Bonin M, Leopold T, Baskaynak G, Dörken B, Ehninger G, Ottmann O, and Jenke A, et al. (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53:313-323.
181. Leffler A, Reckzeh J, and Nau C (2010) Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur J Pharmacol 630:19-28.
182. Li R, Farmer PS, Xie M, Quilliam MA, Pleasance S, Howlett SE, and Yeung PKF (1992) Synthesis, characterization, and Ca2+ antagonistic activity of diltiazem metabolites. J Med Chem 35:3246-3253.
183. Li YP, Zhang LR, Jia M, and Hu XJ (2011) CYP3AP1*3 allele is associated with lipidlowering efficacy of simvastatin and atorvastatin in Chinese women. J Clin Pharmacol 51:181-188.
184. Linnoila M, Insel T, Kilts C, Potter WZ, and Murphy DL (1982) Plasma steady-state concentrations of hydroxylated metabolites of clomipramine. Clin Pharmacol Ther 32:208-211.
185. Lipitor (2012) Product label. Pfizer, New York, NY.
186. Liu J, Chen X, Hu Y, Cheng G, and Zhong D (2010) Quantification of the major metabolites of bromhexine in human plasma using RRLC-MS/MS and its application to pharmacokinetics. J Pharm Biomed Anal 51:1134-1141.
187. Lerena A, Dorado P, Berecz R, González AP, and Peñas-LLedó EM (2004) Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol 59:869-873.
188. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, and Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58:641-649.
189. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, and Eichelbaum M (1985) Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 63:1205-1211.
190. Löscher W (1981) Anticonvulsant activity of metabolites of valproic acid. Arch Int Pharmacodyn Ther 249:158-163.
191. Lötsch J, Stockmann A, Kobal G, Brune K, Waibel R, Schmidt N, and Geisslinger G (1996) Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers. Clin Pharmacol Ther 60:316-325.
192. Lötsch J, Skarke C, Schmidt H, Grösch S, and Geisslinger G (2001) The transfer halflife of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. Anesthesiology 95:1329-1338.
193. Lubega GW and Prichard RK (1991) Interaction of benzimidazole anthelmintics with Haemonchus contortus tubulin: binding affinity and anthelmintic efficacy. Exp Parasitol 73:203-213.
194. Lutz JD, Fujioka Y, and Isoherranen N (2010) Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters. Expert Opin Drug Metab Toxicol 6:1095-1109.
195. Lutz JD and Isoherranen N (2012) Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole. Drug Metab Dispos 40:159-168.
196. Malerba M and Ragnoli B (2008) Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol 4:1119-1129.
197. Malhotra B, Gandelman K, Sachse R, Wood N, and Michel MC (2009) The design and development of fesoterodine as a prodrug of 5-hydroxymethyltolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 16:4481-4489.
198. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, and Danhof M (1992) Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 51:715-728.
199. Mannheimer B and Eliasson E (2010) Drug-drug interactions that reduce the formation of pharmacologically active metabolites: a poorly understood problem in clinical practice. J Intern Med 268:540-548.
200. Martin P, Massol J, Colin JN, Lacomblez L, and Puech AJ (1990) Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry 23: 187-194.
201. Martines C, Gatti G, Sasso E, Calzetti S, and Perucca E (1990) The disposition of primidone in elderly patients. Br J Clin Pharmacol 30:607-611.
202. Mathijssen RHJ, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, and Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182-2194.
203. Maxalt. (2011) Product label. Merck Sharp & Dohme, Whitehouse Station, NJ. Mc
204. Lean MJ and Macdonald RL (1986) Carbamazepine and 10,11-epoxycarbamazepine produce use-and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 238:727-738.
205. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, and Warwick M (2001) Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87 (5A):28B-32B.
206. Medina LR, Garcia LA, and Jung HC (1999) Plasma protein binding of albendazole and its main metabolite albendazole sulfoxide. Rev Mex Cien Farmaceut. 30: 42-45.
207. Meridia. (2010) Product label. Abbott Laboratories, Chicago, IL.
208. Messenger AG and Rundegren J (2004) Minoxidil: mechanisms of action on hair growth. Br J Dermatol 150:186-194.
209. Mikami Y, Sakamoto T, Yazawa K, Gonoi T, Ueno Y, and Hasegawa S (1994) Comparison of in vitro antifungal activity of itraconazole and hydroxy-itraconazole by colorimetric MTT assay. Mycoses 37:27-33.
210. Milton KA, Edwards G, Ward SA, Orme MLE, and Breckenridge AM (1989) Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol 28:71-77.
211. Mirfazaelian A, Rouini MR, and Dadashzadeh S (2003) Time dependent pharmacokinetics of albendazole in human. Biopharm Drug Dispos 24:199-204.
212. Mizushima H, Takanaka K, Abe K, Fukazawa I, and Ishizuka H (2007) Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. Xenobiotica 37:59-73.
213. Molden E, Lunde H, Lunder N, and Refsum H (2006) Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 28:744-749.
214. Montamat SC and Abernethy DR (1987) N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives. Br J Clin Pharmacol 24:185-189.
215. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, and Fleckenstein L (2011) Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J 10:263.
216. Mürdter TE, Kerb R, Turpeinen M, Schroth W, Ganchev B, Böhmer GM, Igel S, Schaeffeler E, Zanger U, and Brauch H, et al. (2012) Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites. Hum Mol Genet 21:1145-1154.
217. Mulder GJ (1992a) Glucuronidation and its role in regulation of biological activity of drugs. Annu Rev Pharmacol Toxicol 32:25-49.
218. Mulder GJ (1992b) Pharmacological effects of drug conjugates: is morphine 6-glucuronide an exception? Trends Pharmacol Sci 13:302-304.
219. Mundo AS, Bonaccorsi A, Bareggi SR, Franco R, Morselli PL, Riva E, and Garattini S (1974) Relationships between tricyclic antidepressant concentrations, 1-3Hnoradrenaline uptake and chronotropic effect in isolated rat atria. Eur J Pharmacol 28:368-375.
220. Murthy BR, Pollack GM, and Brouwer KLR (2002) Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. J Clin Pharmacol 42:569-576.
221. Nakazawa S, Ishiyama M, Oshima Y, and Osada Y (1970) [Bacteriological studies on rifampicin, a new antibiotic. 2. Antimicrobial activity of desacetyl-rifampicin]. Jpn J Antibiot 23:240-241.
222. Nattel S and Talajic M (1988) Recent advances in understanding the pharmacology of amiodarone. Drugs 36:121-131.
223. Nealon C, Dzeing A, Müller-Römer U, Planche T, Sinou V, Kombila M, Kremsner PG, Parzy D, and Krishna S (2002) Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. Antimicrob Agents Chemother 46:3933-3939.
224. Neil A and Terenius L (1981) d-Propoxyphene acts differently from morphine on opioid receptor-effector mechanisms. Eur J Pharmacol 69:33-39.
225. Nelson JC, Bock JL, and Jatlow PI (1983) Clinical implications of 2-hydroxydesipramine plasma concentrations. Clin Pharmacol Ther 33:183-189.
226. Nickolson VJ, Wieringa JH, and Van Delft AML (1982) Comparative pharmacology of mianserin, its main metabolites and 6-azamianserin. Naunyn-Schmied. Arch. Pharmacol. 319:48-55.
227. Nordin C, Bertilsson L, and Siwers B (1985) CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite. Br J Clin Pharmacol 20:411-413.
228. Nordin C and Bertilsson L (1995) Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline. Clin Pharmacokinet 28:26-40.
229. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, MacLeod SL, Kadlubar FF, and Ambrosone CB (2005) Association of genetic variation in tamoxifenmetabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91:249-258.
230. Núñez R and Perel JM (1995) Comparative neurotransmitter reuptake and anticholinergic potencies of the 8-hydroxy metabolites of clomipramine. Psychopharmacol Bull 31:217-221.
231. Nyberg G, Axelsson R, and Mårtensson E (1978) Binding of thioridazine and thioridazine metabolites to serum proteins in psychiatric patients. Eur J Clin Pharmacol 14:341-350.
232. Ochs HR, Greenblatt DJ, Luttkenhurst M, and Verburg-Ochs B (1984) Single and multiple dose kinetics of clobazam and clinical effects during multiple dosing. Eur J Clin Pharmacol 26:499-503.
233. Odds FC and Bossche HV (2000) Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. J Antimicrob Chemother 45:371-373.
234. O'Connor-Semmes RL, Kersey K, Williams DH, Lam R, and Koch KM (2001) Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people. Clin Pharmacol Ther 70: 126-131.
235. Ofori-Adjei D, Ericsson O, Lindström B, and Sjöqvist F (1986) Protein binding of chloroquine enantiomers and desethylchloroquine. Br J Clin Pharmacol 22: 356-358.
236. Ohashi K, Warrington SJ, Kaye CM, Houghton GW, Dennis M, Templeton R, and Turner P (1981) Observations on the clinical pharmacology and plasma concentrations of diacetolol, the major human metabolite of acebutolol. Br J Clin Pharmacol 12:561-565.
237. Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, and Hahne WA (2004) Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol 58 (Suppl 1):41-49.
238. Olsen H, Koppang E, Alvan G, and Mørland J (1994) Carisoprodol elimination in humans. Ther Drug Monit 16:337-340.
239. Olsson B, Brynne N, Johansson C, and Arnberg H (2001) Food increases the bioavailability of tolterodine but not effective exposure. J Clin Pharmacol 41:298-304.
240. Onfi (2011) Product Label. Lundbeck Inc., Deerfield, IL.
241. Onglyza. (2011) Product label. Bristol-Myers Squibb Company, Princeton, NJ.
242. Oosterkamp AJ, Villaverde Herraiz MT, Irth H, Tjaden UR, and van der Greef J (1996) Reversed-phase liquid chromatography coupled on-line to receptor affinity detection based on the human estrogen receptor. Anal Chem 68:1201-1206.
243. Oti-Amoako K, Vozeh S, Ha HR, and Follath F (1990) The relative potency of major metabolites and enantiomers of propafenone in an experimental reperfusion arrhythmia model. J Cardiovasc Pharmacol 15:75-81.
244. Owens MJ, Morgan WN, Plott SJ, and Nemeroff CB (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:1305-1322.
245. Øzbay A, Karamperis N, and Jørgensen KA (2007) A review of the immunosuppressive activity of cyclosporine metabolites: new insights into an old issue. Curr Clin Pharmacol 2:244-248.
246. Paczkowski D, Filipek M, Mielniczuk Z, Andrzejczak J, Popławska W, and Sitkiewicz D (1992) Simultaneous determination of mexiletine and four hydroxylated metabolites in human serum by high-performance liquid chromatography and its application to pharmacokinetic studies. J Chromatogr A 573:235-246.
247. Påhlman I and Gozzi P (1999) Serum protein binding of tolterodine and its major metabolites in humans and several animal species. Biopharm Drug Dispos 20: 91-99.
248. Palmer GC, Murray RJ, Wilson TCM, Eisman MS, Ray RK, Griffith RC, Napier JJ, Fedorchuk M, Stagnitto ML, and Garske GE (1992) Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide. Epilepsy Res 12:9-20.
249. Pang KS (1985) A review of metabolite kinetics. J Pharmacokinet Biopharm 13: 633-662.
250. Patel BN, Sharma N, Sanyal M, and Shrivastav PS (2008) Quantitation of donepezil and its active metabolite 6-O-desmethyl donepezil in human plasma by a selective and sensitive liquid chromatography-tandem mass spectrometric method. Anal Chim Acta 629:145-157.
251. Patsalos PN, Elyas AA, and Zakrzewska JM (1990) Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia. Eur J Clin Pharmacol 39:413-415.
252. Peck RW, Seaber EJ, Dixon RM, Layton GR, Weatherley BC, Jackson SHD, Rolan PE, and Posner J (1998) The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women. Clin Pharmacol Ther 63:342-353.
253. Pilkington T and Brogden RN (1992) Acitretin. A review of its pharmacology and therapeutic use. Drugs 43:597-627.
254. Pluss RG, Orcutt J, and Chidsey CA (1972) Tissue distribution and hypotensive effects of minoxidil in normotensive rats. J Lab Clin Med 79:639-647.
255. Poulsen L, Arendt-Nielsen L, Brøsen K, and Sindrup SH (1996) The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 60:636-644.
256. Peile EB (1985) Relative potencies of spironolactone, canrenone and potassium canrenoate, in Contemporary Trends in Diuretic Therapy (Bruner HR, Berglund G, and Ledingham JGG, eds) pp 47-57, Amsterdam.
257. Pendland SL, Piscitelli SC, Schreckenberger PC, and Danziger LH (1994) In vitro activities of metronidazole and its hydroxy metabolite against Bacteroides spp. Antimicrob Agents Chemother 38:2106-2110.
258. Peng B, Lloyd P, and Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879-894.
259. Penner N, Xu L, and Prakash C (2012) Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol 25:513-531.
260. Piquette-Miller M, Foster RT, Kappagoda CT, and Jamali F (1991) Pharmacokinetics of acebutolol enantiomers in humans. J Pharm Sci 80:313-316.
261. Polettini A and Huestis MA (2001) Simultaneous determination of buprenorphine, norbuprenorphine, and buprenorphine-glucuronide in plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 754:447-459.
262. Powell AC, Elliott SL, and Horowitz JD (1988) Verapamil in unstable angina pectoris: failure to demonstrate a relationship between efficacy and plasma levels. Ther Drug Monit 10:34-38.
263. Prakash C, Shaffer CL, and Nedderman A (2007) Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 26:340-369.
264. Quarterman CP, Kendall MJ, and Jack DB (1981) The effect of age on the pharmacokinetics of metoprolol and its metabolites. Br J Clin Pharmacol 11:287-294.
265. Quiding H, Anderson P, Bondesson U, Boréus LO, and Hynning PA (1986) Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration. Eur J Clin Pharmacol 30:673-677.
266. Raghuram TC, Koshakji RP, Wilkinson GR, and Wood AJJ (1984) Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade. Clin Pharmacol Ther 36:51-56.
267. Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, and Jaillon P (1998) Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 64:192-203.
268. Ralph ED and Amatnieks YE (1980) Relative susceptibilities of Gardnerella vaginalis (Haemophilus vaginalis), Neisseria gonorrhoeae, and Bacteroides fragilis to Metronidazole and its two major metabolites. Sex Transm Dis 7:157-160.
269. Ramanathan R, Reyderman L, Su AD, Alvarez N, Chowdhury SK, Alton KB, Wirth MA, Clement RP, Statkevich P, and Patrick JE (2007) Disposition of desloratadine in healthy volunteers. Xenobiotica 37:770-787.
270. Ramsay L, Asbury M, Shelton J, and Harrison I (1977) Spironolactone and canrenoate-K: relative potency at steady state. Clin Pharmacol Ther 21:602-609.
271. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, and Lyng MB, et al.; Breast International Group (BIG) 1-98 Collaborative Group (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104:441-451.
272. Reidenberg MM, Drayer DE, Levy M, and Warner H (1975) Polymorphic acetylation procainamide in man. Clin Pharmacol Ther 17:722-730.
273. Reis M, Aamo T, Spigset O, and Ahlner J (2009) Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 31:42-56.
274. Reiz JL, Salem P, and Darke AC (2007) Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin. J Clin Pharmacol 47:351-357.
275. Richards DM, Brogden RN, Heel RC, Speight TM, and Avery GS (1984) Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 28: 38-61.
276. Richelson E, Nelson A, and Neeper R (1991) Binding of benzodiazepines and some major metabolites at their sites in normal human frontal cortex in vitro. J Pharmacol Exp Ther 256:897-901.
277. Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, and McNamara RK (2007) Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 32:1715-1726.
278. Roden DM, Reele SB, Higgins SB, Wilkinson GR, Smith RF, Oates JA, and Woosley RL (1980) Antiarrhythmic efficacy, pharmacokinetics and safety of Nacetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol 46:463-468.
279. Rodvold KA (1999) Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 37:385-398.
280. Ronfeld RA, Tremaine LM, and Wilner KD (1997) Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 32 (Suppl 1):22-30.
281. Ronketti F, Ramana AV, Chao-Ming X, Pica-Mattoccia L, Cioli D, and Todd MH (2007) Praziquantel derivatives I: Modification of the aromatic ring. Bioorg Med Chem Lett 17:4154-4157.
282. Rouini MR, Ardakani YH, Moghaddam KA, and Solatani F (2008) An improved HPLC method for rapid quantitation of diazepam and its major metabolites in human plasma. Talanta 75:671-676.
283. Rubens R, Verhaegen H, Brugmans J, and Schuermans V (1972) Difenoxine (R 15403), the active metabolite of diphenoxylate (R 1132). 5. Clinical comparison of difenoxine and diphenoxylate in volunteers and in patients with chronic diarrhea. Double-blind cross-over assessments. Arzneimittelforschung 22:526-529.
284. Ruenitz PC, Bagley JR, and Mokler CM (1983) Metabolism of clomiphene in the rat. Estrogen receptor affinity and antiestrogenic activity of clomiphene metabolites. Biochem Pharmacol 32:2941-2947.
285. Santori L, Rastelli M, Arena B, and Morleo MA (1997) Cyclosporine: update on pharmacology, analytical techniques and therapeutic monitoring. Boll Chim Farm 136:577-588.
286. Sanz MJ, Cortijo J, Taha MA, Cerdá-Nicolás M, Schatton E, Burgbacher B, Klar J, Tenor H, Schudt C, and Issekutz AC, et al. (2007) Roflumilast inhibits leukocyteendothelial cell interactions, expression of adhesion molecules and microvascular permeability. Br J Pharmacol 152:481-492.
287. Sastre J (2008) Ebastine in allergic rhinitis and chronic idiopathic urticaria. Allergy 63 (Suppl 89):1-20.
288. Saurat JH (1999) Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol 41:S2-S6.
289. Schaber G, Stevens I, Gaertner HJ, Dietz K, and Breyer-Pfaff U (1998) Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol 46:453-459.
290. Schachter SC and Tarsy D (2000) Remacemide: current status and clinical applications. Expert Opin Investig Drugs 9:871-883.
291. Schmutz M, Brugger F, Gentsch C, McLean MJ, and Olpe HR (1994) Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 35 (Suppl 5):S47-S50.
292. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CDA, Windass AS, and Raza A (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455-463.
293. Schotte A, Janssen PFM, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, and Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73.
294. Scordo MG, Spina E, Dahl ML, Gatti G, and Perucca E (2005) Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 97: 296-301.
295. Shams M, Hiemke C, and Härtter S (2004) Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum. Ther Drug Monit 26:78-84.
296. Sheldon RS, Hill RJ, Taouis M, and Wilson LM (1991) Aminoalkyl structural requirements for interaction of lidocaine with the class I antiarrhythmic drug receptor on rat cardiac myocytes. Mol Pharmacol 39:609-614.
297. Sheldon RS, Duff HJ, Thakore E, and Hill RJ (1994a) Class I antiarrhythmic drugs: allosteric inhibitors of [3H] batrachotoxinin binding to rat cardiac sodium channels. J Pharmacol Exp Ther 268:187-194.
298. Sheldon R, Thakore E, Wilson L, and Duff H (1994b) Interaction of drug metabolites with the class I antiarrhythmic drug receptor on rat cardiac myocytes. J Pharmacol Exp Ther 269:477-481.
299. Shimoda K, Morita S, Hirokane G, Yokono A, Someya T, and Takahashi S (2000) Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. Pharmacol Toxicol 86: 245-249.
300. Shipkova M, Wieland E, Schütz E, Wiese C, Niedmann PD, Oellerich M, and Armstrong VW (2001) The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 33: 1080-1081.
301. Shipkova M, Armstrong VW, Weber L, Niedmann PD, Wieland E, Haley J, Tönshoff B, and Oellerich M; German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients (2002) Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 24: 390-399.
302. Shon JH, Yeo CW, Liu KH, Lee SS, Cha IJ, and Shin JG (2010) Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants. J Clin Pharmacol 50:195-204.
303. Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, and Woosley RL (1987) Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75:785-791.
304. Sidharta PN, van Giersbergen PL, Halabi A, and Dingemanse J (2011) Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 67:977-984.
305. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, and Larsen F (1997) Steadystate pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9:686-692.
306. Sieghart W (1983) Several new benzodiazepines selectively interact with a benzodiazepine receptor subtype. Neurosci Lett 38:73-78.
307. Silenor. (2010) Product label. Somaxon Pharmaceuticals, San Diego, CA.
308. Simons KJ, Watson WTA, Chen XY, and Simons FER (1989) Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. Clin Pharmacol Ther 45:9-14.
309. Skarke C, Darimont J, Schmidt H, Geisslinger G, and Lötsch J (2003) Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 73:107-121.
310. Smith DA and Dalvie D (2012) Why do metabolites circulate? Xenobiotica 42: 107-126.
311. Smith RB and Kroboth PD (1987) Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacology (Berl) 93:105-112.
312. Smith DL, Vecchio TJ, and Forist AA (1965) Metabolism of antibiotic sulfonylureas in man. Biological half-lives of the p-acetylbenzenesulfonylureas, U-18536 and acetohexamide and their metabolites. Metabolism 14:229-240.
313. Sörgel F, Hasegawa J, Lin ET, and Williams RL (1985) Oral triamterene disposition. Clin Pharmacol Ther 38:306-312.
314. Sohda T, Ikeda H, and Meguro K (1995) Studies on antidiabetic agents. XII. Synthesis and activity of the metabolites of (+/-)-5(-)[p(-)[2-(5-ethyl-2-pyridyl)ethoxy] benzyl]-2,4-thiazolidinedione (pioglitazone). Chem Pharm Bull (Tokyo) 43: 2168-2172.
315. Soriatane. (2011) Product label. Stiefel Laboratories, Research Triangle Park, NC.
316. Sprycel. (2011) Product label. Bristol-Meyers Squibb Company, Princeton, NJ.
317. St-Pierre MV, Xu X, and Pang KS (1988) Primary, secondary, and tertiary metabolite kinetics. J Pharmacokinet Biopharm 16:493-527.
318. Stäubli M, Troendle A, Schmid B, Balmer P, Kohler B, Studer H, and Bircher J (1985) Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites. Eur J Clin Pharmacol 29:417-423.
319. Stangier J, Stähle H, Rathgen K, and Fuhr R (2008) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47:47-59.
320. Stimmel GL, Dopheide JA, and Stahl SM (1997) Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 17:10-21.
321. Sugimoto H, Iimura Y, Yamanishi Y, and Yamatsu K (1995) Synthesis and structureactivity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J Med Chem 38:4821-4829.
322. Sutfin TA, Perini GI, Molnar G, and Jusko WJ (1988) Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. J Clin Psychopharmacol 8:48-53.
323. Szymura-Oleksiak J, Wyska E, and Wasieczko A (2001) Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. Psychopharmacology (Berl) 154:38-42.
324. Tadori Y, Forbes RA, McQuade RD, and Kikuchi T (2011) In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol 668:355-365.
325. Takeuchi H, Yokota S, Shimada S, Ohtani Y, Miura S, and Kubo H (1993) Pharmacokinetics of amoxapine and its active metabolites in healthy subjects. Curr. Ther. Res. 53:427-434.
326. Tamta H, Kalra S, and Mukhopadhyay AK (2006) Biochemical characterization of some pyrazolopyrimidine-based inhibitors of xanthine oxidase. Biochemistry (Mosc) 71 (Suppl 1):S49-S54.
327. Tanis SP, Parker TT, Colca JR, Fisher RM, and Kletzein RF (1996) Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone. J Med Chem 39:5053-5063.
328. Tatsumi M, Groshan K, Blakely RD, and Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249-258.
329. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, and Yocca FD (1995) Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 56 (Suppl 6):3-11.
330. Tenconi LT, Pallanza R, Beretta E, and Furesz S (1970) Biological properties of desacetylrifampicin. A metabolite of rifampicin. Progr Antimicrob Anticancer Chemother Proc Int Congr Chemother 1:346-352.
331. Thomas PC and Jones RB (1977) The effects of clomipramine and desmethylclomipramine on the in vitro uptake of radiolabelled 5-HT and noradrenaline into rat brain cortical slices. J Pharm Pharmacol 29:562-563.
332. Ticku MK and Olsen RW (1978) Interaction of barbiturates with dihydropicrotoxinin binding sites related to the GABA receptor-ionophore system. Life Sci 22: 1643-1651.
333. Timmer CJ, Verheul HAM, and Doorstam DP (2002) Pharmacokinetics of tibolone in early and late postmenopausal women. Br J Clin Pharmacol 54:101-106.
334. Tomson T and Bertilsson L (1984) Potent therapeutic effect of carbamazepine-10,11-epoxide in trigeminal neuralgia. Arch Neurol 41:598-601.
335. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, and Declèves X (2010) Interaction of drugs of abuse and maintenance treatments with human Pglycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol 13:905-915.
336. Treiber G, Wex T, Schleyer E, Troeger U, Hosius C, and Malfertheiner P (2008) Imatinib for hepatocellular cancer-focus on pharmacokinetic/pharmacodynamic modelling and liver function. Cancer Lett 260:146-154.
337. Trellu M, Filali-Ansary A, Françon D, Adam R, Lluel P, Dubruc C, and Thénot JP (2004) New metabolic and pharmacokinetic characteristics of thiocolchicoside and its active metabolite in healthy humans. Fundam Clin Pharmacol 18:493-501.
338. Trifiletti RR and Snyder SH (1984) Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors. Mol Pharmacol 26:458-469.
339. Turnheim K, Krivanek P, and Oberbauer R (1999) Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol 48: 501-509.
340. Ujhelyi MR, Klamerus KJ, Vadiei K, O'Rangers E, Izard M, Neefe DL, Zimmerman JJ, and Chow MSS (1996) Disposition of intravenous amiodarone in subjects with normal and impaired renal function. J Clin Pharmacol 36:122-130.
341. Ulens C, Daenens P, and Tytgat J (1999) Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res 44:568-578.
342. Urien S, Claudepierre P, Meyer J, Brandt R, and Tillement JP (1992) Comparative binding of etretinate and acitretin to plasma proteins and erythrocytes. Biochem Pharmacol 44:1891-1893.
343. Veenendaal JR, Parkinson AD, Kere N, Rieckmann KH, and Edstein MD (1991) Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine. Eur J Clin Pharmacol 41:161-164.
344. Vernekar SKV, Hallaq HY, Clarkson G, Thompson AJ, Silvestri L, Lummis SCR, and Lochner M (2010) Toward biophysical probes for the 5-HT3 receptor: structureactivity relationship study of granisetron derivatives. J Med Chem 53:2324-2328.
345. Vippagunta SR, Dorn A, Matile H, Bhattacharjee AK, Karle JM, Ellis WY, Ridley RG, and Vennerstrom JL (1999) Structural specificity of chloroquine-hematin binding related to inhibition of hematin polymerization and parasite growth. J Med Chem 42:4630-4639.
346. Vishwanathan K, Babalola K, Wang J, Espina R, Yu L, Adedoyin A, Talaat R, Mutlib A, and Scatina J (2009) Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem Res Toxicol 22:311-322.
347. Voelger KD (1991) Animal experiments and human studies with the phase-II metabolite of triamterene. Arzneimittelforschung 41:499-506.
348. Volpe DA, McMahon Tobin GA, Mellon RD, Katki AG, Parker RJ, Colatsky T, Kropp TJ, and Verbois SL (2011) Uniform assessment and ranking of opioid m receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol 59:385-390.
349. Vos RME, Krebbers SFM, Verhoeven CHJ, and Delbressine LPC (2002) The in vivo human metabolism of tibolone. Drug Metab Dispos 30:106-112.
350. Vozeh S, Uematsu T, Guentert TW, Ha HR, and Follath F (1985) Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects. Clin Pharmacol Ther 37:575-581.
351. Vozeh S, Haefeli W, Ha HR, Vlcek J, and Follath F (1990) Nonlinear kinetics of propafenone metabolites in healthy man. Eur J Clin Pharmacol 38:509-513.
352. Waldeck K, Larsson B, and Andersson KE (1997) Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 157:1093-1097.
353. Walker GS, Ryder TF, Sharma R, Smith EB, and Freund A (2011) Validation of isolated metabolites from drug metabolism studies as analytical standards by quantitative NMR. Drug Metab Dispos 39:433-440.
354. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, and DeVane CL (2004) The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by Pglycoprotein. Int J Neuropsychopharmacol 7:415-419.
355. Way WL and Schou J (1979) Entrance into brain of dextropropoxyphene and the toxic metabolite norpropoxyphene. Arch Toxicol Suppl (Suppl 2):367-370.
356. Wellbutrin (2011) Product Label. GlaxoSmithKline, Research Triangle Park, NC.
357. Westhoff F and Blaschke G (1992) High-performance liquid chromatographic determination of the stereoselective biotransformation of the chiral drug praziquantel. J Chromatogr 578:265-271.
358. Whitehouse LW, Menzies A, Mueller R, and Pontefract R (1994) Ketoconazoleinduced hepatic phospholipidosis in the mouse and its association with de-N-acetyl ketoconazole. Toxicology 94:81-95.
359. Wiseman LR and Markham A (1996) Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 52:606-623.
360. Wong H, Dockens RC, Pajor L, Yeola S, Grace JE Jr, Stark AD, Taub RA, Yocca FD, Zaczek RC, and Li YW (2007) 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. Drug Metab Dispos 35:1387-1392.
361. Wong RP, Salman S, Ilett KF, Siba PM, Mueller I, and Davis TME (2011) Desbutyllumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob Agents Chemother 55:1194-1198.
362. Wong YC, Wo SK, and Zuo Z (2012) Investigation of the disposition of loxapine, amoxapine and their hydroxylated metabolites in different brain regions, CSF and plasma of rat by LC-MS/MS. J Pharm Biomed Anal 58:83-93.
363. Wooding-Scott RA, Smalley J, Visco J, and Slaughter RL (1988) The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine. Br J Clin Pharmacol 26:415-421.
364. Wüster M and Herz A (1978) Opiate agonist action of antidiarrheal agents in vitro and in vivo-findings in support for selective action. Naunyn Schmiedebergs Arch Pharmacol 301:187-194.
365. Wyss PA, Rosenthaler J, Nüesch E, and Aellig WH (1991) Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects. Eur J Clin Pharmacol 41:597-602.
366. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjöqvist F, Eliasson E, and Dahl ML (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71:89-98.
367. Yamada H, Ishii K, Ishii Y, Ieiri I, Nishio S, Morioka T, and Oguri K (2003) Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain. J Toxicol Sci 28:395-401.
368. Yeung CK, Fujioka Y, Hachad H, Levy RH, and Isoherranen N (2011) Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency. Clin Pharmacol Ther 89:105-113.
369. Yong CL, Kunka RL, and Bates TR (1980) Factors affecting the plasma protein binding of verapamil and norverapamil in man. Res Commun Chem Pathol Pharmacol 30:329-339.
370. Yono M, Yoshida M, Wada Y, Kikukawa H, Takahashi W, Inadome A, Seshita H, and Ueda S (1999) Pharmacological effects of tolterodine on human isolated urinary bladder. Eur J Pharmacol 368:223-230.
371. Young PW, Buckle DR, Cantello BCC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, and Kallender H, et al. (1998) Identification of highaffinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferatoractivated receptor gamma. J Pharmacol Exp Ther 284:751-759.
372. Zhang D and Comezoglu SN (2007) ADME studies in animals and humans: experimental design, metabolite profiling and identification, and data presentation, in Drug Metabolism in Drug Design and Development (Zhang et al. eds) pp 573-609. Wiley Online, Hoboken, NJ.
373. Zoble RG, Kirsten EB, and Brewington J (1989) Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group. Clin Pharmacol Ther 45:535-541.